Ajanta Pharma Limited
AJANTPHARM.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$426.04B
Close$
$4638.95
39.4% upside
Current Fair Value
39.4% upsideUndervalued by 39.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $426.04 Billion |
|---|---|
| Enterprise Value | $426.04 Billion |
| Dividend Yield | $60.00 (1.76%) |
| Earnings per Share | $84.53 |
| Beta | 0.18 |
| Outstanding Shares | 124,935,624 |
Return
| Return on Equity | 25.07% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 37.54 |
|---|---|
| PEG | 121.52 |
| Price to Sales | 7.2 |
| Price to Book Ratio | 9.19 |
| Enterprise Value to Revenue | 7.38 |
| Enterprise Value to EBIT | 29.04 |
| Enterprise Value to Net Income | 37 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$23.18
Average shareholder expectationRevenue Estimate
$15.08 B
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$25.13
Average shareholder expectationRevenue Estimate
$16.07 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Ajanta Pharma Limited
10,421 employees
CEO: Yogesh Mannalal Agrawal Operating as a specialized pharmaceutical company, Ajanta Pharma Limited, together with its subsidiaries, is involved in the entire lifecycle of finished drug formulations, from their development and manufacturing to market distribution....